Molecular Pharmacodynamics of New Oral Drugs Used in the Treatment of Multiple Sclerosis

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2014 May 31

PMID 24876766

Citations 16

Authors

Luigi di Nuzzo

Rosamaria Orlando

Carla Nasca

Ferdinando Nicoletti

Affiliations

Soon will be listed here.

Abstract

New oral drugs have considerably enriched the therapeutic armamentarium for the treatment of multiple sclerosis. This review focuses on the molecular pharmacodynamics of fingolimod, dimethyl fumarate (BG-12), laquinimod, and teriflunomide. We specifically comment on the action of these drugs at three levels: 1) the regulation of the immune system; 2) the permeability of the blood-brain barrier; and 3) the central nervous system. Fingolimod phosphate (the active metabolite of fingolimod) has a unique mechanism of action and represents the first ligand of G-protein-coupled receptors (sphingosine-1-phosphate receptors) active in the treatment of multiple sclerosis. Dimethyl fumarate activates the nuclear factor (erythroid-derived 2)-related factor 2 pathway of cell defense as a result of an initial depletion of reduced glutathione. We discuss how this mechanism lies on the border between cell protection and toxicity. Laquinimod has multiple (but less defined) mechanisms of action, which make the drug slightly more effective on disability progression than on annualized relapse rate in clinical studies. Teriflunomide acts as a specific inhibitor of the de novo pyrimidine biosynthesis. We also discuss new unexpected mechanisms of these drugs, such as the induction of brain-derived neurotrophic factor by fingolimod and the possibility that laquinimod and teriflunomide regulate the kynurenine pathway of tryptophan metabolism.

Citing Articles

Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems.

Nosaka T, Naito T, Akazawa Y, Takahashi K, Matsuda H, Ohtani M PLoS One. 2025; 20(3):e0314581.

PMID: 40048440 PMC: 11884705. DOI: 10.1371/journal.pone.0314581.

Alopecia associated with dimethyl fumarate treatment for multiple sclerosis.

Abicic A, Adamec I, Habek M Wien Med Wochenschr. 2023; 173(11-12):287-289.

PMID: 36920580 DOI: 10.1007/s10354-023-01007-7.

New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate.

Matteo P, Federico D, Emanuela M, Giulia R, Tommaso B, Alfredo G Pharmaceutics. 2022; 14(12).

PMID: 36559226 PMC: 9788528. DOI: 10.3390/pharmaceutics14122732.

Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study.

Renaud C, Ziros P, Mathias A, Pot C, Sykiotis G Antioxidants (Basel). 2022; 11(5).

PMID: 35624879 PMC: 9138003. DOI: 10.3390/antiox11051015.

Sphingosine-1-Phosphate Signaling in Ischemic Stroke: From Bench to Bedside and Beyond.

Zhang S, Xiao J, Chen M, Zhou L, Shang K, Qin C Front Cell Neurosci. 2021; 15:781098.

PMID: 34916911 PMC: 8669352. DOI: 10.3389/fncel.2021.781098.

References

Miron V, Ludwin S, Darlington P, Jarjour A, Soliven B, Kennedy T . Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010; 176(6):2682-94. PMC: 2877831. DOI: 10.2353/ajpath.2010.091234. View

Meissner M, Doll M, Hrgovic I, Reichenbach G, Konig V, Hailemariam-Jahn T . Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol. 2011; 131(6):1356-64. DOI: 10.1038/jid.2011.46. View

Kipp M, Amor S . FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scler. 2012; 18(3):258-63. DOI: 10.1177/1352458512438723. View

Vladimirova O, OConnor J, Cahill A, Alder H, Butunoi C, Kalman B . Oxidative damage to DNA in plaques of MS brains. Mult Scler. 1998; 4(5):413-8. DOI: 10.1177/135245859800400503. View

Peng H, Guerau-de-Arellano M, Mehta V, Yang Y, Huss D, Papenfuss T . Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012; 287(33):28017-26. PMC: 3431702. DOI: 10.1074/jbc.M112.383380. View

Belladonna M, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti M . Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol. 2006; 177(1):130-7. DOI: 10.4049/jimmunol.177.1.130. View

Balatoni B, Storch M, Swoboda E, Schonborn V, Koziel A, Lambrou G . FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull. 2007; 74(5):307-16. DOI: 10.1016/j.brainresbull.2007.06.023. View

Cannon R, Peart J, Hawkins B, Campos C, Miller D . Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A. 2012; 109(39):15930-5. PMC: 3465435. DOI: 10.1073/pnas.1203534109. View

Molendijk M, Bus B, Spinhoven P, Kaimatzoglou A, Oude Voshaar R, Penninx B . A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume--a genuine effect or a winners curse?. Am J Med Genet B Neuropsychiatr Genet. 2012; 159B(6):731-40. DOI: 10.1002/ajmg.b.32078. View

10.

Cohen J, Chun J . Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011; 69(5):759-77. DOI: 10.1002/ana.22426. View

11.

Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

12.

Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D . Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol. 2002; 168(9):4781-7. DOI: 10.4049/jimmunol.168.9.4781. View

13.

Chun J, Hartung H . Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33(2):91-101. PMC: 2859693. DOI: 10.1097/WNF.0b013e3181cbf825. View

14.

Lin S, Lisi L, Dello Russo C, Polak P, Sharp A, Weinberg G . The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 2011; 3(2). PMC: 3072764. DOI: 10.1042/AN20100033. View

15.

Layseca-Espinosa E, Pedraza-Alva G, Montiel J, Del Rio R, Fierro N, Gonzalez-Amaro R . T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol. 2003; 74(6):1083-93. DOI: 10.1189/jlb.0303095. View

16.

Miron V, Jung C, Kim H, Kennedy T, Soliven B, Antel J . FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2007; 63(1):61-71. DOI: 10.1002/ana.21227. View

17.

Lee D, Gold R, Linker R . Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci. 2012; 13(9):11783-11803. PMC: 3472775. DOI: 10.3390/ijms130911783. View

18.

Zou L, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B . Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology. 2002; 42(5):731-9. DOI: 10.1016/s0028-3908(02)00015-1. View

19.

Jackson S, Giovannoni G, Baker D . Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation. 2011; 8:76. PMC: 3152910. DOI: 10.1186/1742-2094-8-76. View

20.

Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y . An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236(2):313-22. DOI: 10.1006/bbrc.1997.6943. View